MR-OPERA:多中心多厂商验证基于合成CT的磁共振-only前列腺放疗计划
本研究在170例前列腺癌患者中验证了商用软件MriPlanner将磁共振图像转换为合成CT的剂量学准确性,涉及4个中心、4台MR扫描仪和2种磁场强度。结果显示合成CT与CT计划的剂量分布平均差异小于0.3%,全局2%/2mm伽马通过率全身平均99.12%、PTV平均99.97%,表明该MR-only工作流程临床可行且稳健。
要点
- 合成CT与CT剂量分布所有评估器官和靶区的平均差异均低于0.3%。
- 全身伽马通过率平均99.12%(0.63%,1SD),PTV平均99.97%(0.13%,1SD),标准为2%/2mm全局伽马。
- 差异在各中心间一致,支持MR-only工作流程跨磁场强度、厂商和治疗技术的稳健性。
核心结论
- 基于MriPlanner的合成CT转换方法可临床用于前列腺癌MR-only放疗计划,靶区和危及器官剂量分布与CT计划差异极小。
研究设计与样本
- 多中心多厂商验证研究,纳入170例前列腺癌患者,4个参与中心使用基于云服务的MriPlanner(Spectronic Medical)图集法合成CT生成软件。
- 每例患者按临床实践创建并批准CT治疗计划,将合成CT与CT刚性配准后在合成CT上重新计算临床治疗计划,比较剂量分布。
- 研究纳入4台MR扫描仪和2种磁场强度,治疗技术包括容积旋转调强放疗、调强放疗和常规治疗,使用2个治疗计划系统和不同剂量计算算法。
主要发现
- 多中心多厂商总体合成CT与CT剂量分布的平均剂量差异在所有评估器官和靶区均低于0.3%。
- 全局2%/2mm伽马评估显示全身体积平均通过率99.12%(0.63%,1SD),计划靶区平均通过率99.97%(0.13%,1SD)。
临床怎么用
- 在前列腺癌放疗中可采用基于MriPlanner的MR-only工作流程生成合成CT用于治疗计划,减少CT扫描需求。
- 该工作流程在不同MR厂商、磁场强度和治疗技术下剂量差异小且中心间一致,具备临床推广的稳健性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To validate the dosimetric accuracy and clinical robustness of a commercially available software for magnetic resonance (MR) to synthetic computed tomography (sCT) conversion, in an MR imaging-only workflow for 170 prostate cancer patients. METHODS AND MATERIALS: The 4 participating centers had MriPlanner (Spectronic Medical), an atlas-based sCT generation software, installed as a cloud-based service. A T2-weighted MR sequence, covering the body contour, was added to the clinical protocol. The MR images were sent from the MR scanner workstation to the MriPlanner platform. The sCT was automatically returned to the treatment planning system. Four MR scanners and 2 magnetic field strengths were included in the study. For each patient, a CT-treatment plan was created and approved according to clinical practice. The sCT was rigidly registered to the CT, and the clinical treatment plan was recalculated on the sCT. The dose distributions from the CT plan and the sCT plan were compared according to a set of dose-volume histogram parameters and gamma evaluation. Treatment techniques included volumetric modulated arc therapy, intensity modulated radiation therapy, and conventional treatment using 2 treatment planning systems and different dose calculation algorithms. RESULTS: The overall (multicenter/multivendor) mean dose differences between sCT and CT dose distributions were below 0.3% for all evaluated organs and targets. Gamma evaluation showed a mean pass rate of 99.12% (0.63%, 1 SD) in the complete body volume and 99.97% (0.13%, 1 SD) in the planning target volume using a 2%/2-mm global gamma criteria. CONCLUSIONS: Results of the study show that the sCT conversion method can be used clinically, with minimal differences between sCT and CT dose distributions for target and relevant organs at risk. The small differences seen are consistent between centers, indicating that an MR imaging-only workflow using MriPlanner is robust for a variety of field strengths, vendors, and treatment techniques.
引用
- Persson E, Gustafsson C, Nordström F, et al. MR-OPERA: A Multicenter/Multivendor Validation of Magnetic Resonance Imaging-Only Prostate Treatment Planning Using Synthetic Computed Tomography Images. Int J Radiat Oncol Biol Phys. 2017. PMID: 28843375. doi:10.1016/j.ijrobp.2017.06.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。